Cargando…

Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine

The present study aims to determine whether 17DD-YF-specific humoral and cellular immunological memory is maintained 8-years after primary vaccination with subdoses (10,447IU;3,013IU;587IU;158IU;31IU). For this purpose, this follow-up study was carried out in a subset of volunteers (n = 98) original...

Descripción completa

Detalles Bibliográficos
Autores principales: da Costa-Rocha, Ismael Artur, Campi-Azevedo, Ana Carolina, Peruhype-Magalhães, Vanessa, Coelho-dos-Reis, Jordana Grazziela, Fradico, Jordana Rodrigues Barbosa, Souza-Lopes, Thalles, Reis, Laise Rodrigues, Freire, Larissa Chaves, Costa-Pereira, Christiane, Mambrini, Juliana Vaz de Melo, Maia, Maria de Lourdes de Sousa, de Lima, Sheila Maria Barbosa, de Noronha, Tatiana Guimarães, Xavier, Janaina Reis, Camacho, Luiz Antonio Bastos, de Albuquerque, Elizabeth Maciel, Farias, Roberto Henrique Guedes, de Castro, Thalita da Matta, Homma, Akira, Romano, Alessandro Pecego Martins, Domingues, Carla Magda, Martins, Reinaldo de Menezes, Teixeira-Carvalho, Andréa, Martins-Filho, Olindo Assis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598206/
https://www.ncbi.nlm.nih.gov/pubmed/31293563
http://dx.doi.org/10.3389/fimmu.2019.01211
Descripción
Sumario:The present study aims to determine whether 17DD-YF-specific humoral and cellular immunological memory is maintained 8-years after primary vaccination with subdoses (10,447IU;3,013IU;587IU;158IU;31IU). For this purpose, this follow-up study was carried out in a subset of volunteers (n = 98) originally enrolled in the dose-response study in 2009 and 46 non-vaccinated controls. Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94, 82, 83, 94, 80, and 91%, correspondingly), only doses above 587IU elicited similar iterative proportion of seropositivity rates, calculated as a progressive decrease on seropositivity rates along time (89, 80, 80, and 91%, respectively) as compared to 158IU and 31IU (68 and 46%, respectively). Noteworthy were the strong positive correlations (“EMCD4,EMCD8” and “TNFCD8,IFNCD8”) observed in most subdoses, except for 31IU. Major similarities underscored the preserved antibody titers and the outstanding levels of EMCD8, relevant correlates of protection for YF-specific immunity. These findings provide evidences to support the regular use of dose sparing strategy for YF vaccine in adults.